Sydney, Australia – 7 February 2025: Pancreatic cancer treatment device company OncoSil Medical Limited (ASX:OSL) will host an investor webinar on Tuesday 11 February 2025.
The webinar will be presented by OncoSil’s Chief Executive Officer & Managing Director, Nigel Lange, and will be followed by a short Q&A session.
In his webinar presentation, Mr Lange will discuss recent developments in the OncoSil™ device’s commercialisation strategy, including:
- An update on the German Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA) approval for the Directive for testing the new treatment method: "Endoscopic injection-implantation of 32Plabeled microparticles in unresectable, locally advanced pancreatic tumors."
- The authorisation by the German Institute for the Hospital Remuneration System (InEK) for 120 German hospitals to negotiate funding for the OncoSil™ device classification under the innovation funding (NUB) program with the statutory health insurance (SHI) companies during the annual budget negotiations.
- The receipt of Medical Device Regulation certification from BSI, the EU Notified Body, including the lifting of existing post-market restrictions and it’s impacts.
- Latest updates about ongoing clinical trials (TRIPP-FFX and PANCOSIL)
OncoSil Medical Investor Webinar Registration Details:
DATE: Tuesday 11 February 2025
TIME: 3.00PM AEDT
FORMAT: Zoom
Links to Reference Documents:
- G-BA approval received for OncoSil device
- 120 German hospitals entitled to negotiate fee for OncoSil
- OncoSil Medical receives MDR approval
Please register in advance using the following link:
https://us02web.zoom.us/webinar/register/WN_Otjt_CNpQUazqUdgJPBudw
About us:
About OncoSil Medical
OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for longterm survival.
The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient’s pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.
The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.
While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.
To learn more, please visit: www.oncosil.com
Contact details:
For more information, please contact:
Mr. Nigel Lange
CEO & Managing Director
E: [email protected]
T: +49 30 300 149 3043
Mr. Christian Dal Cin
CFO & Company Secretary
E: [email protected]
T: +61 3 9824 5254
Media & Investor Enquiries
Ms. Julia Maguire
The Capital Network
Media and Investor Enquiries
E: [email protected]
T: +61 2 8999 3699
